Navigation Links
Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
Date:10/26/2008

WASHINGTON, Oct. 26 /PRNewswire/ -- Sequoia Pharmaceuticals presented positive results today from two studies on SPI-256, a novel investigational HIV protease inhibitor (PI). One study based on an in vitro analysis demonstrates that the mode of interaction of SPI-256 with HIV protease provides a rationale for its high potency and high genetic barrier to resistance. The second study conducted in healthy volunteers demonstrates that SPI-256 is generally safe and well tolerated in humans and is amenable to boosting by pharmacokinetic enhancers (PKEs). The data were presented at the 48th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th annual Infectious Diseases Society of America (IDSA) joint meeting held in Washington, D.C.

"Two ongoing significant needs in contemporary HIV therapy are: new agents that have activity against mutant virus and also have a high genetic barrier to developing resistance; and new agents that can boost the pharmacokinetic levels of existing drugs," said Martin Markowitz, MD, professor and clinical director at the Aaron Diamond AIDS Research Center. "These data on SPI-256 look very promising and address the need for new agents with activity against protease inhibitor-resistant virus as well as the development of resistance. I look forward to further advancements and innovations in HIV that will address our needs in the treatment community from a resistance, as well as a PK, point of view."

Data on SPI-256 at this conference

Discovery and in vitro activity of SPI-256

Scientists from Sequoia Pharmaceuticals presented their structure-based approach that led to the development of SPI-256. Prior to discovering SPI-256, Sequoia scientists examined three-dimensional structures of wild-type and drug-resistant mutant HIV proteases bound to selected inhibitors. By analyzing these structures, the Sequoia scientists were able to identify a subset of main-chain and active-site atoms of
'/>"/>

SOURCE Sequoia Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Transparency Market Research ... (MCA) Market for Cellulosics, Agrochemicals, Surfactants, Thioglycolic Acid (TGA) ... Growth, Trends and Forecast 2014 - 2020". The global ... in 2013 and is anticipated to reach USD 1,046.7 ... during the forecast period from 2014 to 2020. In ...
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com announces ... available in its catalogue: Wireless ... RFID, Zigbee, UWB WWAN, WMAN, WLAN and ... Kalorama Information,s Wireless Opportunities ... Zigbee, UWB WWAN, WMAN, WLAN and other ...
(Date:8/20/2014)... , Aug. 20, 2014   Ventana Medical ...  Group, today announced that its VENTANA System for ... in the European Union for routine pathology, including ... consisting of VENTANA Virtuoso software coupled with either ... HT slide scanner, provides automated digital slide creation, ...
Breaking Medicine Technology:Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 2Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 3Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 4Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 2Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 4Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 5Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 6Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 7Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 8Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 9Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 10Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 11Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 12Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 13Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 14Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 15Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 16Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3
... Week Dec. 2-8, HARRISBURG, Pa., Dec. 3 ... wants all children in,Pennsylvania to help stop spreading germs ... officials are celebrating National Hand Washing Awareness Week,Dec. 2-8, ... "Hand washing is one of the most important ...
... ALTO, Calif., Dec. 3 Telik, Inc.,(Nasdaq: TELK ... 1,dose-escalation study of TELINTRA(R) (ezatiostat HCl) Tablets at the ... presentation is,scheduled for Saturday, December 8, 2007, from 5:30 ... Georgia World Congress Center in Atlanta. The presentation,(Abstract # ...
Cached Medicine Technology:Health Secretary Reminds Kids to Stop Germs - Wash Hands 2
(Date:8/20/2014)... Line: A study in Australia examined patient and ... (a marker of tumor cell growth) in an ... cancer in patients. , Author: ... Victoria, Australia, and colleagues. , Background: The ... cell division) has been connected with prognosis and ...
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 Hundreds ... on behalf of women who were allegedly injured due ... forward in New Jersey’s Bergen County Superior Court, Bernstein ... issued on August 15, 2014, the Court has established ... for Mirena lawsuits that are part of the proceeding’s ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. ... cells grow may help doctors diagnose and treat the most ... have found that the deadliest skin cancers occur most often ... long history of sun exposure. These lesions also grow ... cell growth -- called "high mitotic rate" -- is ...
(Date:8/20/2014)... Aug. 20, 2014 A common approach to treating ... did not improve survival chances for people who suddenly ... at the University of Pittsburgh School of Medicine. , ... One , suggest acute hemodialysis, an aggressive method that ... may not provide a definitive benefit to the patient. ...
(Date:8/20/2014)... Research from Columbia University Medical Center shows that nerves ... and that blocking nerve signals using surgery or Botox ... The study was conducted by the laboratory of Timothy ... PhD, in Norway and is published in today,s issue ... long observed that human and mouse cancers contain a ...
Breaking Medicine News(10 mins):Health News:Patient, tumor characteristics for high-mitotic rate melanoma 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 4Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... Brookdale Senior Living Inc. (NYSE: BKD ) today ... Ohlendorf, Co-President and Chief Financial Officer, will make a presentation ... Lynch 2009 Health Care Conference in New York, NY on ... presentation is being audio webcast live and can be accessed ...
... New FDA-Approved Chemical Entity for Topical Acne Treatment in a ... that it has entered into a co-promotion agreement with Allergan ... for acne vulgaris. Representing the first new molecule in a ... acne in patients 12 years of age and older, ACZONE(R) ...
... Ore., May 11 The following statement is from Regence ... in response to today,s announcement by a group of private-sector ... spending growth rate to save as much as $2 trillion ... to help control health care costs in our nation. ...
... Reiterates Going Concern Opinion to Comply with NASDAQ ... Encorium Group, Inc. (Nasdaq: ENCO ... (CRO) that provides design, development, and management capabilities ... of the world,s leading pharmaceutical companies, today announced ...
... Cardium Therapeutics (NYSE Amex: CXM ) ... quarter ended March 31, 2009, and on recent ... made significant progress in the first quarter 2009 ... on the InnerCool Therapies and Tissue Repair Company ...
... LOS ANGELES (EMBARGOED UNTIL MAY 11, 2009; 3 pm Central ... following scenario: a woman comes into the office complaining of ... pain, and the stress test results suggest coronary artery disease, ... arteries. She is then referred for an angiogram to look ...
Cached Medicine News:Health News:SkinMedica to Co-Promote ACZONE(R) (dapsone) Gel 5% to Pediatricians in the U.S. 2Health News:SkinMedica to Co-Promote ACZONE(R) (dapsone) Gel 5% to Pediatricians in the U.S. 3Health News:SkinMedica to Co-Promote ACZONE(R) (dapsone) Gel 5% to Pediatricians in the U.S. 4Health News:Regence Optimistic About Health Industry Leaders' Pledge to Cut Health Care Costs 2Health News:Encorium Group Enters into Non-Binding Letters of Intent 2Health News:Encorium Group Enters into Non-Binding Letters of Intent 3Health News:Encorium Group Enters into Non-Binding Letters of Intent 4Health News:Encorium Group Enters into Non-Binding Letters of Intent 5Health News:Cardium Reports on First Quarter 2009 Financial Results and Recent Developments 2Health News:Cardium Reports on First Quarter 2009 Financial Results and Recent Developments 3Health News:Cardium Reports on First Quarter 2009 Financial Results and Recent Developments 4Health News:Cardium Reports on First Quarter 2009 Financial Results and Recent Developments 5Health News:Cardium Reports on First Quarter 2009 Financial Results and Recent Developments 6Health News:Cardium Reports on First Quarter 2009 Financial Results and Recent Developments 7Health News:Cardium Reports on First Quarter 2009 Financial Results and Recent Developments 8Health News:Cardium Reports on First Quarter 2009 Financial Results and Recent Developments 9Health News:Cardium Reports on First Quarter 2009 Financial Results and Recent Developments 10Health News:Cardium Reports on First Quarter 2009 Financial Results and Recent Developments 11Health News:Study: Women with hard to diagnose chest pain symptoms at higher risk for cardiovascular events 2Health News:Study: Women with hard to diagnose chest pain symptoms at higher risk for cardiovascular events 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: